Credit Suisse Group restated their neutral rating on shares of Bioverativ (NASDAQ:BIVV) in a research note published on Thursday morning. The firm currently has a $65.00 target price on the biotechnology company’s stock.
BIVV has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Bioverativ from a buy rating to a hold rating in a research note on Wednesday, January 3rd. Morgan Stanley reiterated an underweight rating and set a $47.00 price objective (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Piper Jaffray Companies reiterated an overweight rating and set a $71.00 price objective on shares of Bioverativ in a research note on Monday, October 23rd. Argus upgraded shares of Bioverativ from a hold rating to a buy rating and set a $64.00 price objective on the stock in a research note on Wednesday, September 20th. Finally, Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the stock a hold rating in a research note on Monday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $62.53.
Shares of Bioverativ (BIVV) traded up $1.36 during trading on Thursday, reaching $64.11. 712,830 shares of the company’s stock were exchanged, compared to its average volume of 788,887. Bioverativ has a 12-month low of $40.99 and a 12-month high of $65.09.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. The firm had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s revenue was up 27.2% compared to the same quarter last year. equities analysts predict that Bioverativ will post 2.69 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN acquired a new stake in shares of Bioverativ in the 3rd quarter valued at approximately $124,500,000. Woodford Investment Management Ltd acquired a new stake in shares of Bioverativ in the 3rd quarter valued at approximately $85,455,000. Jackson Square Partners LLC acquired a new stake in Bioverativ during the 3rd quarter worth approximately $99,336,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ during the 3rd quarter worth approximately $96,827,000. Finally, ValueAct Holdings L.P. acquired a new stake in Bioverativ during the 3rd quarter worth approximately $72,514,000. Institutional investors own 96.03% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/20/bioverativ-bivv-given-neutral-rating-at-credit-suisse-group.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.